Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares Repurchased
Ratios

Sanofi (SNY) EBIAT (2016 - 2025)

Historic EBIAT for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to -$7.7 billion.

  • Sanofi's EBIAT fell 151368.8% to -$7.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.7 billion, marking a year-over-year increase of 9107.33%. This contributed to the annual value of $8.9 billion for FY2025, which is 4591.43% up from last year.
  • According to the latest figures from Q4 2025, Sanofi's EBIAT is -$7.7 billion, which was down 151368.8% from $10.1 billion recorded in Q3 2025.
  • Sanofi's EBIAT's 5-year high stood at $10.1 billion during Q3 2025, with a 5-year trough of -$7.7 billion in Q4 2025.
  • Over the past 5 years, Sanofi's median EBIAT value was $1.9 billion (recorded in 2021), while the average stood at $2.0 billion.
  • The largest annual percentage gain for Sanofi's EBIAT in the last 5 years was 50772.26% (2025), contrasted with its biggest fall of 151368.8% (2025).
  • Quarter analysis of 5 years shows Sanofi's EBIAT stood at $1.3 billion in 2021, then soared by 147.62% to $3.2 billion in 2022, then crashed by 118.58% to -$600.4 million in 2023, then surged by 190.95% to $546.1 million in 2024, then plummeted by 1513.69% to -$7.7 billion in 2025.
  • Its last three reported values are -$7.7 billion in Q4 2025, $10.1 billion for Q3 2025, and $7.3 billion during Q2 2025.